<DOC>
	<DOCNO>NCT00230529</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety infliximab ( Remicade ) patient plaque-type psoriasis .</brief_summary>
	<brief_title>A Safety Efficacy Study Infliximab ( Remicade ) Patients With Plaque Type Psoriasis</brief_title>
	<detailed_description>The purpose study investigate safety possible usefulness infliximab therapy patient severe plaque psoriasis . In previous small study infliximab 33 patient psoriasis , 80 % patient treat infliximab show improvement psoriasis symptom first 3 infusion , 20 % patient receive placebo show improvement . The patient receive infusion infliximab either 3 5 mg/kg placebo week 0,2,6 . Patients significant psoriasis week 26 receive additional infusion .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Must 18 year age old time enrollment may male female Have diagnosis plaquetype psoriasis least 6 month prior screen Have plaquetype psoriasis cover least 10 % total BSA baseline Have previously receive PUVA and/or systemic treatment psoriasis Have nonplaque form psoriasis Have history druginduced psoriasis Are pregnant , nursing , plan pregnancy within 12 month enrollment Have previous treatment infliximab therapeutic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Plaque-type Psoriasis</keyword>
	<keyword>infliximab</keyword>
	<keyword>Remicade</keyword>
	<keyword>biologics</keyword>
</DOC>